Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Cellectar Biosciences

  • James Caruso, Cellectar Biosciences

Cellectar Biosciences is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company plans to develop proprietary drugs independently and through research and development (R&D) collaborations. The core drug development strategy is to leverage our PDC platform to develop therapeutics that specifically target treatment to cancer cells. Through R&D collaborations, the company’s strategy is to generate near-term capital, supplement internal resources, gain access to novel molecules or payloads, accelerate product candidate development and to broaden our proprietary and partnered product pipelines.

The company’s lead PDC therapeutic, CLR 131, is in a Phase 1 clinical study in patients with R/R MM and a Phase 2 clinical study in R/R MM and a range of B-cell malignancies. The company plans to initiate a Phase 1 study with CLR 131 in pediatric solid tumors and lymphomas.

  • Date:Tuesday, February 12
  • Time:11:00 AM - 11:15 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23550
  • Goal for Presentation:To attract investors and partners
  • Company Website:cellectar.com
  • Company HQ City:Florham Park
  • Company HQ State:New Jersey
  • Company HQ Country:United States
  • Ticker:CLRB
  • Exchange:NASDAQ
  • CEO/Top Company Official:James Caruso
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:CLR 131
  • Development Phase of Primary Product:Phase II
Speakers
James Caruso
Cellectar Biosciences
Back